PMID-34304009 – 5-Amino-1MQ Pharmacokinetic and Oral Bioavailability
Awosemo O, Bhatt DK, McHardy SF, Watowich SJ, Neelakantan H. Development and validation of an LC-MS/MS method for the quantitation of 5-amino-1-methylquinolinium, a novel NNMT inhibitor, and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2021;205:114255.
Quick Reference
| Property | Value |
|---|---|
| PMID | 34304009 |
| DOI | 10.1016/j.jpba.2021.114255 |
| Year | 2021 |
| Journal | Journal of Pharmaceutical and Biomedical Analysis |
| Study Type | Pharmacokinetic study |
| Evidence Level | V |
| Sample | Sprague-Dawley rats, IV and oral dosing arms |
| Peptide(s) Studied | 5-Amino-1MQ |
Key Findings
- Developed and validated a sensitive LC-MS/MS analytical method for quantifying 5-Amino-1MQ in biological matrices
- Oral bioavailability of 5-Amino-1MQ was 38.4% in rats — remarkably high for a small molecule with quaternary amine character
- Maximum plasma concentration (Cmax) reached 2252 ng/mL after oral dosing, confirming robust systemic absorption
- The assay demonstrated excellent linearity, precision, and accuracy across the calibration range
- PK profile supports feasibility of oral dosing regimens for clinical application
- Half-life and clearance parameters were characterized, enabling dose prediction for future studies
Study Design
Sprague-Dawley rats received 5-Amino-1MQ via intravenous injection or oral gavage. Serial blood samples were collected at multiple time points. Plasma concentrations were measured using a newly developed and validated LC-MS/MS method. Pharmacokinetic parameters (Cmax, Tmax, AUC, half-life, clearance, volume of distribution, oral bioavailability) were calculated using non-compartmental analysis.
Limitations
- Rat PK parameters may not directly predict human pharmacokinetics due to species differences in metabolism
- Single-dose PK study — no assessment of accumulation or changes in PK with repeated dosing
- Only one dose level tested for each route
- No assessment of tissue distribution or target engagement (NNMT inhibition in vivo)
- No evaluation of metabolites
Clinical Relevance
This study is essential for the clinical development of 5-Amino-1MQ as an oral therapeutic. The 38.4% oral bioavailability is clinically viable and supports the oral capsule formulations currently available (such as the Ageless Peps 50mg capsules). The validated analytical method also enables future human PK studies. The Cmax of 2252 ng/mL indicates that therapeutic concentrations can be achieved orally, which is a key milestone for any drug development program.
Related
#research #animal-in-vivo #5-Amino-1MQ #evidence-level-V